← Human Trials & Peer-Reviewed Studies
Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea
Plain-language guide to PMID 14960741 (2004): single-blind randomized controlled trial study of BNP (Nesiritide) in 452 patients.
Key Facts
- PMID
- 14960741
- Journal
- The New England journal of medicine
- Year
- 2004
- Study type
- Randomized Controlled Trial
- Authors
- Mueller C et al. (8 authors)
- DOI
- 10.1056/NEJMoa031681
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at BNP (Nesiritide).
B-type natriuretic peptide levels are higher in patients with congestive heart failure than in patients with dyspnea from other causes.
Who Took Part
The study group was 452 patients.
By PubMed's age tags, the people studied were adults, middle-aged adults, older adults and people over 80, both men and women.
The researchers conducted a prospective, randomized, controlled study of 452 patients who presented to the emergency department with acute dyspnea: 225 patients were randomly assigned to a diagnostic strategy involving the measurement of B-type natriuretic peptide levels with the use of a rapid bedside assay, and 227 were assessed in a standard manner.
The time to discharge and the total cost of treatment were the primary end points.
How the Study Was Run
The design is described as randomized and single-blind.
Because people in this BNP (Nesiritide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
In this single-blind BNP (Nesiritide) study one party knew the assignments and the other did not.
What Was Measured
B-type natriuretic peptide levels are higher in patients with congestive heart failure than in patients with dyspnea from other causes.
The subject headings attached to it are Acute Disease, Biomarkers, Dyspnea, Emergency Service, Hospital, Heart Failure, Hospital Costs and Hospitalization.
What This Means in Plain Language
The paper is a randomized and single-blind study of BNP (Nesiritide) in 452 patients.
With several hundred people or more, it is a fairly large study for this kind of research.
Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2004 (The New England journal of medicine), a journal based in United States.
More context: the BNP (Nesiritide) compound page, all human trials.
Our Notes on the Compound
BNP (Nesiritide): B-type natriuretic peptide, a 32-amino-acid heart hormone; nesiritide (Natrecor) is a recombinant form used in acute heart failure.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.